MTOR and cancer: Studies also report that PI3K/Akt/mTOR is activated, in particular in 30%–50% of PC, mainly due to the amplification of gene encoding components, advocating that targeted inhibition of those individual components of the signaling cascade might be a solid strategy for cancer therapy (Gomez-Pinillos and Ferrari 2012).